Patents by Inventor Anders Asbjørn Jensen

Anders Asbjørn Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-HTagonists for use in treatment of depression
    Patent number: 11642336
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: July 6, 2021
    Date of Patent: May 9, 2023
    Assignee: LOPHORA APS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A agonists for use in treatment of depression
    Patent number: 11633390
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: April 25, 2023
    Assignee: LOPHORA APS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20220062257
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: June 16, 2021
    Publication date: March 3, 2022
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HTagonists for use in treatment of depression
    Patent number: 11246860
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Grant
    Filed: November 5, 2020
    Date of Patent: February 15, 2022
    Assignee: Lophora ApS
    Inventors: Jesper Langgaard Kristensen, Anders Asbjørn Jensen, Emil Märcher-Rørsted, Sebastian Leth-Petersen
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20210330658
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: July 6, 2021
    Publication date: October 28, 2021
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn JENSEN, Emil MÄRCHER-RØRSTED, Sebastian LETH-PETERSEN
  • 5-HT2A AGONISTS FOR USE IN TREATMENT OF DEPRESSION
    Publication number: 20210137908
    Abstract: The present invention relates to agonists of the 5-HT2A serotonin receptors and their medical uses. In one aspect the invention relates to 5-HT2A agonists of formula (I). In second aspect, the invention relates to selective 5-HT2A agonists of formula (II). In another aspect, the invention relates to mixed 5-HT2A/5-HT2C agonists of formula (III). In yet another aspect, the invention relates to 5-HT2A agonists for use in the treatment of a depressive disorder, more particular a 5-HT2A agonist for the use in the treatment of treatment-resistant depression.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 13, 2021
    Applicant: Lophora ApS
    Inventors: Jesper Langgaard KRISTENSEN, Anders Asbjørn JENSEN, Emil MÄRCHER-RØRSTED, Sebastian LETH-PETERSEN
  • SELECTIVE INHIBITORS OF EXCITATORY AMINO ACID TRANSPORTER SUBTYPE 1 (EAAT1/GLAST)
    Publication number: 20130345420
    Abstract: The invention is the discovery of the use of the class of compounds represented by Formula I, as selective inhibitors of excitatory amino acid transporter (EAAT) subtype 1 (EAAT1) and its rodent ortholog L-glutamate/L-aspartate transporter (GLAST) for the study of function and distribution of EAAT1/GLAST in the central nervous system and studies of the physiological and pathological functions of the EAAT1/GLAST subtype in native tissues, cultured neurons, and/or animal models for CNS disorders.
    Type: Application
    Filed: September 19, 2011
    Publication date: December 26, 2013
    Inventors: Lennart Bunch, Anders Asbjørn Jensen
  • SELECTIVE INHIBITORS OF EXCITATORY AMINO ACID TRANSPORTER SUBTYPE 1 (EAAT1/GLAST)
    Publication number: 20120035361
    Abstract: The invention is the discovery of the use of the class of compounds represented by Formula I, as selective inhibitors of excitatory amino acid transporter (EAAT) subtype 1 (EAAT1) and its rodent ortholog L-glutamate/L-aspartate transporter (GLAST) for the study of function and distribution of EAAT1/GLAST in the central nervous system and studies of the physiological and pathological functions of the EAAT1/GLAST subtype in native tissues, cultured neurons, and/or animal models for CNS disorders.
    Type: Application
    Filed: September 19, 2011
    Publication date: February 9, 2012
    Inventors: Lennart Bunch, Anders Asbjørn Jensen